Addressing the Overlooked Aspect of Estate Planning: Navigating Life...

Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs.  Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It's a watershed move that could unlock a vast new patient population for Novo Nordisk and

Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift

Transforming Healthcare with AI and Machine Learning Innovations Personalized Medicine:...

Conno Christou doesn’t leave things to chance. He tracks his sleep with a Whoop band, cross-references it with an Oura ring, and gets nearly 100 biomarkers checked every year. He had been doing the annual bloodwork for four consecutive years, following the protocols of longevity researchers like Peter Attia and Rhonda Patrick. He was optimizing